sqeezing the quick buck, page-22

chaching - good point. I amy be wrong, but so far as I know, PRR has no product sales to support its R&D activities and ST has, until recently, been funding this. With PRR's entry to the US market, ST is no longer required to fulfil the funding role - presumably other, cheaper, forms of funding will become available. So imagine the (unlikely) scenario where Nasdaq listing is withdrawn and ST funding is not there... ouch! In my graph, under another thread, that would take the share price into the Disaster Area. Yes, this is a very unlikely scenario but I do like to consider all possibilites.